BioSpace

In this episode of Denatured, sponsored by Cytiva, Jennifer Smith-Parker speaks to Nicolas Pivet, VP & GM, Manufacturing & Digital Solutions at Cytiva. In this episode, we discuss how biopharma has long invested in more data and visibility, yet many programs still face delays and scale-up surprises. The real challenge isn’t information overload—it’s building confidence in the decisions that steer scientific progress from development through commercialization.

This episode is presented in partnership with Cytiva.

Host
Jennifer Smith-Parker, Director of Insights, BioSpace

Guest
Nicolas Pivet, VP & GM, Manufacturing & Digital Solutions, Cytiva

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations

Johnson & Johnson beat analyst expectations in the third quarter but left Wall Street wanting more; BMS dominated the news cycle on Monday with a Phase 3 win validating its $4.1 billion RayzeBio buy and mixed data in a late-stage pulmonary fibrosis trial; Revolution Medicines’ newly approved pancreatic cancer drug works better for patients with certain mutations; and Caribou Biosciences may be on its way out.

In this episode of Denatured, you’ll hear from Jennifer McMahon, partner at Seroba and Joey Mason, venture partner at Claret Capital. We dig into how venture debt buys time when equity can’t — and how Europe’s funding gaps, tranching habits and slower urgency shape who uses it well.
Host
Jennifer C. Smith-Parker, Director of Insights, BioSpace
Guests
Jennifer McMahon, Partner, Seroba
Joey Mason, Venture Partner, Claret Capital
Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

New data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this week, including Novartis’ nearly $8 billion bet on mRNA drugs with China’s Abogen Biosciences; and could Sarepta Therapeutics turn things around from last year’s annus horribilis?

In this episode of Denatured, you’ll hear from Max Bronstein, CEO of Aviva Strategies and Teresa Barnes, Chief Executive Warrior of PF Warriors. We dig into why U.S. patients are losing access to rare disease trials happening abroad and how the FAIR Act’s accelerated, harmonized reviews could help the U.S. keep pace while getting lifesaving studies to patients faster.
Host
⁠Jennifer C. Smith-Parker, Director of Insights, BioSpace

Guests
Max Bronstein, CEO, Aviva Strategies
Teresa Barnes, Chief Executive Warrior, PF Warriors
Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.